Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Older patients started on oral antidiabetic therapy with a sulfonylurea have significantly higher risk for cardiovascular disease (CVD) events than patients started on metformin.

Related Videos
Gary Price, MD, MBA
Gary Price, MD, MBA
Gary Price, MD, MBA
Gary Price, MD, MBA
Gary Price, MD, MBA
Veronica Villareal, MHA/MBA
Veronica Villareal, MHA/MBA
Veronica Villareal, MHA/MBA
Veronica Villareal, MHA/MBA
Related Content

Hospitals see improving finances

March 28th 2023

How scientific denialism undermines public health

March 9th 2023

Emergency departments are practicing bad medicine at patients’ expense

March 28th 2023

It's not just money: why disparities in access to health care have been growing

December 14th 2022

Why Avoiding “Diworsification” is a Good Idea

March 27th 2023

Residents’ clinical rotation has little effect on length of patient hospital stays

March 27th 2023

Hospitals see improving finances

March 28th 2023

How scientific denialism undermines public health

March 9th 2023

Emergency departments are practicing bad medicine at patients’ expense

March 28th 2023

It's not just money: why disparities in access to health care have been growing

December 14th 2022

Why Avoiding “Diworsification” is a Good Idea

March 27th 2023

Residents’ clinical rotation has little effect on length of patient hospital stays

March 27th 2023

Hospitals see improving finances

March 28th 2023

How scientific denialism undermines public health

March 9th 2023

Emergency departments are practicing bad medicine at patients’ expense

March 28th 2023

It's not just money: why disparities in access to health care have been growing

December 14th 2022

Why Avoiding “Diworsification” is a Good Idea

March 27th 2023

Residents’ clinical rotation has little effect on length of patient hospital stays

March 27th 2023
© 2023 MJH Life Sciences

All rights reserved.